Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Glaukos Corporation

In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Glaukos, with a price target of $195.00. Maeder covers the He...

Glaukos (GKOS) Gets a Buy from Piper Sandler

Glaukos Corp. (($GKOS)) has held its Q2 earnings call. Read on for the main highlights of the call. Glaukos Corp. struck an upbeat tone on its late...

Glaukos Corp. Earnings Call Highlights Robust Growth

Truist Financial analyst Richard Newitter reiterated a Buy rating on Glaukos today and set a price target of $215.00. Newitter covers the Healthcar...

Truist Financial Keeps Their Buy Rating on Glaukos (GKOS)

In a report released today, Adam Maeder from Piper Sandler reiterated a Buy rating on Glaukos, with a price target of $195.00. Maeder covers the He...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GKOS	$184.15	-0.79%	625.59K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GKOS	$184.15	-0.8%	625.59K
3
4
5
6

GKOS

Get Glaukos Corporation Data in Excel

Get Glaukos Corporation Data in Excel